Tesamorelin for Visceral Fat: UK Guide

Tesamorelin for visceral fat is a topic of growing interest, particularly among adults with HIV-associated lipodystrophy, where excess abdominal fat accumulation poses real metabolic risks. Tesamorelin is a synthetic growth hormone-releasing hormone analogue that stimulates the pituitary gland to increase endogenous growth hormone production, promoting the breakdown of visceral adipose tissue. This article explains how tesamorelin works, who it is prescribed for, what the clinical evidence shows, its safety profile, and how it can be accessed in the UK, where it currently holds no MHRA marketing authorisation.

What is tesamorelin and how does it reduce visceral fat?

Tesamorelin is a synthetic GHRH analogue that stimulates the pituitary gland to produce growth hormone, which promotes lipolysis and preferentially reduces visceral adipose tissue in adults with HIV-associated lipodystrophy. It is not a general weight-loss medicine and is not licensed in the UK.

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that reduces visceral fat by stimulating the pituitary gland to produce more endogenous growth hormone.^[1][2] Growth hormone, in turn, promotes lipolysis, the breakdown of stored fat.^[1][4] In adults with HIV-associated lipodystrophy, clinical trials have demonstrated a preferential reduction in visceral adipose tissue, the metabolically active fat that accumulates around the abdominal organs, with comparatively modest effects on subcutaneous fat or overall body weight. This mechanism differs from direct growth hormone administration in that it works through the body's own regulatory feedback system rather than bypassing it, though whether this translates into a meaningfully different side-effect profile has not been established in head-to-head trials.

Tesamorelin is administered by subcutaneous injection. Dosing and formulation details differ between the two US presentations (Egrifta and Egrifta SV) and should be verified against the relevant prescribing information; there is no UK-licensed formulation.

Visceral fat is not simply a cosmetic concern. Excess visceral adiposity is associated with insulin resistance, dyslipidaemia, and increased cardiovascular risk, making its reduction a clinically meaningful goal in certain patient populations.

It is important to note that tesamorelin is not a general weight-loss medicine and is not licensed in the UK for obesity management. Its clinical application is narrow and defined by specific underlying conditions. Patients and clinicians considering tesamorelin should understand that its effects are tied to its hormonal mechanism and are not equivalent to those of GLP-1 receptor agonists or other weight-management medicines currently available in the UK.

Who is tesamorelin prescribed for in the UK?

Tesamorelin has no MHRA marketing authorisation in the UK and can only be prescribed on an unlicensed, named-patient basis by a specialist clinician with documented clinical rationale and informed consent. It is not available through standard NHS prescribing pathways.

Tesamorelin does not hold a marketing authorisation granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, meaning it is not a licensed medicine for routine prescribing in this country.^[10] In the United States, tesamorelin (brand name Egrifta) is approved by the FDA specifically for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, a condition in which antiretroviral therapy causes abnormal fat redistribution.^[3][2] No equivalent UK licence exists.

In the UK, a medicine without a marketing authorisation can only be prescribed on an unlicensed or specials basis, under the clinical responsibility of the prescribing doctor, when there is a clear unmet clinical need and no licensed alternative is suitable. This is sometimes referred to as named-patient supply. Any such prescribing must comply with MHRA guidance on the use of unlicensed medicines, and the prescriber should document the clinical rationale and obtain informed consent for unlicensed use. The Specialist Pharmacy Service (SPS) provides practical guidance for NHS clinicians on the governance of specials prescribing.

Practically, this means tesamorelin is not available through standard NHS prescribing pathways, and no NICE technology appraisal or guideline exists for any indication. Clinicians considering it for a patient with HIV-associated lipodystrophy would typically do so within a specialist setting, such as an HIV medicine or endocrinology clinic, and would need to source the medicine through a licensed specials importer. The British HIV Association (BHIVA) publishes guidance on metabolic complications and lipodystrophy in people living with HIV, which provides relevant clinical context for UK specialists.^[13]

Patients should not attempt to obtain tesamorelin without a formal clinical assessment and a valid prescription from a registered UK medical practitioner.

How well does tesamorelin actually work for belly fat reduction?

Randomised controlled trials show tesamorelin reduces visceral fat area by approximately 15 to 20 percent over 26 weeks in adults with HIV-associated lipodystrophy, but fat returns when treatment stops. Evidence does not support its use in people without this specific condition.

Clinical trial evidence shows that tesamorelin produces meaningful reductions in visceral adipose tissue in adults with HIV-associated lipodystrophy. Pivotal randomised controlled trials, including studies published in the New England Journal of Medicine and the Journal of Clinical Endocrinology and Metabolism, demonstrated reductions in visceral fat area of approximately 15 to 20 percent compared with placebo over 26 weeks, as measured by CT imaging.^[1][2] These findings formed the basis for FDA approval in the United States. Importantly, visceral fat tends to return when treatment is stopped, suggesting the effect depends on continued use rather than a lasting metabolic change.^[2][4]

Beyond visceral fat, tesamorelin has been associated in these trials with modest improvements in triglyceride levels and some patient-reported quality-of-life measures related to body image in the HIV lipodystrophy population.^[2][6] Effects on cardiovascular outcomes, insulin sensitivity, and long-term metabolic health have not been established in large, long-term trials.

All efficacy data relate to adults with HIV-associated lipodystrophy. Evidence for tesamorelin in people without this condition, including those with general obesity or metabolic syndrome, is limited and does not currently support its use in those populations. Extrapolating results from the HIV lipodystrophy trials to other groups would not be clinically appropriate. Patients seeking treatment for visceral fat accumulation outside this specific context should discuss licensed options with their GP or a specialist, as several evidence-based treatments are available through established UK pathways.

What side effects and safety risks should I know about?

Common side effects include fluid retention, arthralgia, injection site reactions, paraesthesia, and elevated blood glucose; carpal tunnel syndrome is also recognised. Tesamorelin is contraindicated in active malignancy and requires monitoring of IGF-1 and blood glucose throughout treatment.

Tesamorelin carries a range of side effects that reflect its mechanism of action through growth hormone stimulation. Commonly reported adverse effects in clinical trials include:

• Fluid retention, presenting as peripheral oedema or joint swelling

• Arthralgia and myalgia, particularly in the hands, wrists, and knees

• Injection site reactions, including erythema, pruritus, and pain

• Paraesthesia, a tingling or numbness sensation, often in the extremities

• Elevated blood glucose, as growth hormone can impair insulin sensitivity; this is particularly relevant in patients with pre-existing diabetes or impaired glucose tolerance

Carpal tunnel syndrome is a recognised adverse effect associated with growth hormone axis stimulation and has been reported with tesamorelin use.^[4][7]

Because tesamorelin raises insulin-like growth factor 1 (IGF-1) levels, there are concerns about stimulating growth in pre-existing malignancies, and it is generally contraindicated in patients with active malignancy.^[4][7] It should also be used with caution in patients with a history of pituitary disorders or those receiving glucocorticoid therapy, which can blunt the GHRH response. These contraindications and precautions are described in the FDA Prescribing Information for Egrifta and Egrifta SV, which represents the most authoritative available source in the absence of a UK SmPC.

Monitoring during treatment should include baseline and periodic assessment of IGF-1 levels and blood glucose or HbA1c, given the effects of growth hormone on glucose metabolism.^[4][7] Patients with diabetes or impaired glucose tolerance require particular attention and should ensure their specialist team is aware of any tesamorelin use.

Tesamorelin is not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception during treatment.

Because tesamorelin is unlicensed in the UK, any suspected adverse reactions should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk, in addition to informing the prescribing clinician. Patients experiencing significant joint pain, signs of fluid overload, or unexpected changes in blood glucose should contact their GP or specialist promptly. In the event of a severe allergic reaction, call 999 immediately.

Can I get tesamorelin on the NHS or only privately?

Tesamorelin is not routinely commissioned by the NHS and has no NICE appraisal; private access is possible via the unlicensed medicines route but requires specialist oversight, licensed importation, and full patient-funded costs. An Individual Funding Request to an ICB is possible but not guaranteed.

Tesamorelin is not routinely commissioned by the NHS. Because it holds no MHRA marketing authorisation and no NICE technology appraisal or guideline exists for any indication, there is no standard NHS pathway for its use. NHS Integrated Care Boards (ICBs) do not routinely fund medicines in this position, though in exceptional circumstances a patient may be considered for funding through an Individual Funding Request (IFR), which allows ICBs to consider cases where a patient has an unusual clinical need not covered by existing policy. Such requests are assessed on a case-by-case basis and are not guaranteed.

Private access is theoretically possible through the unlicensed medicines route, but this requires a specialist clinician to take explicit responsibility for the prescribing decision, document the clinical rationale, obtain informed consent for unlicensed use, and source the medicine through a licensed specials importer or a registered pharmacy with appropriate import authorisation. This is a complex and relatively uncommon pathway, and the costs involved, including specialist consultation, importation, and ongoing monitoring, are borne entirely by the patient.

For patients concerned about visceral fat accumulation, particularly in the context of metabolic disease or HIV-related lipodystrophy, the most appropriate first step is a referral to a relevant NHS specialist, such as an endocrinologist or HIV physician, who can assess whether any intervention is clinically indicated and what licensed options may be suitable. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, though tesamorelin is not a licensed UK medicine and would not form part of a standard weight-management consultation.

Patients should be cautious about online sources offering tesamorelin without a valid UK prescription, as purchasing unlicensed medicines from unverified suppliers carries significant safety risks. When using any online pharmacy or prescribing service, you can verify the pharmacy on the GPhC register at pharmacyregulation.org (or the PSNI register if you are in Northern Ireland), check that the online clinical service is registered with the Care Quality Commission (CQC) at cqc.org.uk, and confirm that your prescriber is registered with the General Medical Council at gmc-uk.org.

Scientific References

1. Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV.
2. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
3. FDA approves tesamorelin for HIV-related lipodystrophy.
4. Spotlight on tesamorelin in HIV-associated lipodystrophy.
5. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients.
6. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
7. Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.
8. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.
9. Growth hormone and glycemic metabolism.
10. Medicines and Healthcare products Regulatory Agency.
11. Supply unlicensed medicinal products (specials).
12. Guidance on prescribing.
13. Antiretroviral medicines: updated advice on body-fat changes and lactic acidosis.

Frequently Asked Questions